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Pathological behaviors such as problem gambling or
shopping are characterized by compulsive choice
despite alternative options and negative costs. Rein-
forcement learning algorithms allow a computation
of prediction error, a comparison of actual and ex-
pected outcomes, which updates our predictions
and influences our subsequent choices. Using a rein-
forcement learning model, we show data consistent
with the idea that dopamine agonists in susceptible
individuals with Parkinson’s disease increase the
rate of learning from gain outcomes. Dopamine
agonists also increase striatal prediction error
activity, thus signifying a ‘‘better than expected’’
outcome. Thus, our findings are consistent with
a model whereby a distorted estimation of the gain
cue underpins a choice bias toward gains.
INTRODUCTION
Maladaptive behaviors such as pathological gambling or shop-
ping are, by definition, problems of compulsive choice despite
alternative options and negative costs. We used a model of rein-
forcement learning to deconstruct the decision-making process
underlying these compulsive behaviors. Reinforcement learning
algorithms allow a computation of prediction error (d) in classical
and instrumental conditioning, which acts as a teaching signal to
update our predictions and influence our subsequent choices
(Sutton and Barto, 1998). Converging animal and human studies,
the latter measuring the blood oxygen level dependent (BOLD)
signal in fMRI studies suggest that phasic activity of midbrain
dopamine encodes d, resulting in increased activity to unex-
pected rewards and decreased activity to unexpected reward
omissions (Bayer and Glimcher, 2005; O’Doherty et al., 2003;
Pessiglione et al., 2006; Schultz et al., 1997). Abnormalities in
the expression of d have been hypothesized to play a role in
pathologies such as substance use disorders (Redish, 2004)
but have not yet been demonstrated in human studies of behav-
ioral pathology.
Here, we focused on compulsive disorders triggered in Parkin-
son’s disease (PD) by dopamine agonists (DA) (Dagher andRobbins, 2009; Voon et al., 2007; Weintraub et al., 2006). A
constellation of pathological behaviors, including gambling,
shopping, binge eating, and hypersexuality, is seen in 17% of
those on DA (Voon et al., 2007). These behaviors are associated
with factors predisposing to general substance use disorders,
such as higher novelty seeking, impulsivity, and alcohol abuse
disorders, thus emphasizing a common underlying susceptibility
(Voon et al., 2007). The study of DA-induced compulsive behav-
iors provides a unique opportunity to unravel the core biology of
‘‘behavioral addiction’’ in susceptible individuals.
In normal volunteers, levodopa improves learning from posi-
tive outcomes and is associated with enhanced ventral striatal
BOLD signal modeling prediction error (d) (Pessiglione et al.,
2006). Levodopa, which is a precursor to dopamine, increases
presynaptic and extrasynaptic dopamine levels and thus may
enhance physiological phasic dopaminergic activity. In PD
patients (without compulsive behaviors), the combination of
levodopa and DA can worsen learning from negative outcomes,
with effects of learning from positive outcomes being more vari-
able (Frank et al., 2004, 2007b). DA, in contrast to levodopa, toni-
cally stimulates specific dopaminergic receptor subtypes. Frank
et al. have suggested that the tonic stimulation of DA may block
a phasic dopamine dip that serves as a crucial component of the
learning signal (Frank et al., 2004, 2007b). DA may also interact
with an underlying susceptibility. For instance, pathological
gambling in the general population is associated with decision-
making impairments such as disadvantageous choices on
gambling tasks and greater impulsive choice (Goudriaan et al.,
2005; Petry, 2001). In PD patients with dopaminergic medica-
tion-related pathological gambling, a gambling task with both
win and loss outcomes has previously been shown to increase
ventral striatal dopamine release (Steeves et al., 2009).
In this fMRI study, we aimed to describe brain mechanisms
involved in DA modulation of learning from gain and loss
outcomes in a population susceptible to compulsive behaviors.
Consequently, we compared PD patients with problem gambling
and shopping (DD) with matched PD controls on and off DA and
also with matched normal volunteers. We applied a reinforce-
ment learning model to a probabilistic learning task and
restricted our primary hypotheses to the ventral striatum. We
hypothesized a group (DD patients compared to PD controls)
by medication interaction effect during gain learning reflecting
underlying susceptibility where DA would be associated with
faster learning from gain outcomes along with greater ventralNeuron 65, 135–142, January 14, 2010 ª2010 Elsevier Inc. 135
Figure 1. Learning Task
(A) Subjects chose between probabilistic stimulus
pairs from three conditions: gain, loss, and neutral.
One stimulus pair was associated with an 80:20
probability of either gaining, losing, or ‘‘looking
at’’ $10:$0, respectively, with the opposite contin-
gency in the other stimulus pair.
(B) Behavioral outcomes for model parameters.
The learning rate (a) and temperature or choice
randomness (b) are represented for gain and loss
conditions. Higher a and b scores represent faster
learning and greater temperature, respectively.
Parkinson disease (PD) patients with problem
gambling or compulsive shopping (DD) and PD
controls are represented on and off dopamine
agonists. Error bars represent standard error
of the mean (*p < 0.05 for mixed measures
ANOVA group by medication interaction effects).
NV = Age- and gender-matched normal volun-
teers.
(C) Learning curve. The learning curve plots indi-
cate actual behavioral choices during gain and
loss conditions. See also Tables S1, S2, and S3.
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controls. Given that different striatal regions, the amygdala,
and orbitofrontal and anterior insular cortices are implicated in
the coding of d, we also examined these regions and relevant
findings purely on a descriptive basis (O’Doherty et al., 2003;
Pessiglione et al., 2006; Seymour et al., 2004).RESULTS
Patient and Disease Characteristics
Behavioral outcomes were obtained from 14 DD patients, 14 PD
controls and 16 normal volunteers. Eleven DD patients, 11 PD
controls and 16 normal volunteers were scanned. Ten of the
DD patients had decreases in DA dose from the original presen-
tation of pathological behaviors with concomitant increases in
levodopa doses. The other four patients were not able to tolerate
changes in dose and/or their behaviors were controlled with
external behavioral controls. There were no differences in demo-
graphic or disease characteristics (Table S1). The DD patients
did not have problems with gambling or shopping behaviors
prior to PD onset. DD patients had greater working memory
impairments compared to PD controls as discussed more exten-
sively elsewhere (Table S1) (Voon et al., 2009).Medications
PD subjects were scanned either off DA or on DA in a pseudor-
andomized order. When scanned off DA, DA were held a mean of
21 (SD 4.5) hr and levodopa held overnight before scanning.
When scanned on DA, levodopa was held overnight and DA
administered 2 hr before scanning. The mean DA dose of the
DD patients (2 hr before scanning: 67.35 [SD 11.31] levodopa
dose equivalents per day) was not significantly different from
the PD controls (61.25 [SD 9.71] levodopa dose equivalents136 Neuron 65, 135–142, January 14, 2010 ª2010 Elsevier Inc.per day) (t = 1.35, df = 21, p = 0.19) (Hobson et al., 2002). The
DA dose administered on the day of scanning ranged from 2 to
6 mg for ropinirole and 0.5 to 1 mg for pramipexole.Reinforcement Learning
Using a probabilistic gain and loss learning task (Figure 1A), we
assessed actual learning behavior as ‘‘correct’’ response
selected and the Q-learning reinforcement model-based param-
eters of learning rate (a), and temperature (b), an index of choice
randomness.Behavioral Outcomes
During gain learning, there were no main effects. We identified
a susceptibility by medication interaction effect for the ‘‘correct’’
response selected and also for the model-based parameter of
gain learning rate (a) (Figure 1B). Pairwise analyses showed
that DA were associated with a greater percentage of gain
cues selected and faster learning rates (higher a) in DD patients.
This effect of DA was not observed in PD controls. We have illus-
trated the ‘‘correct’’ response selected over the course of the
trial (Figure 1C).
During loss learning, there were no main effects. We again
observed a susceptibility by medication interaction effect for
the behavioral measure of ‘‘correct’’ response selected (avoid-
ance of the loss cue) and the model-based parameters of
a and b (Figure 1B). Pairwise analyses showed that DA were
associated with a lower percentage of the ‘‘correct’’ response
selected, lower a and lower b in PD controls. This effect of DA
was not observed in DD patients. Statistics and other behavioral
outcomes of gain and loss learning are reported in Table S1.
Note that there was no correlation between a, b, and actual
choices for gain and loss learning (R2: a = 0.11; b = 0.09; %
‘‘correct’’ choices = 0.14; p > 0.05). There were also no
Figure 2. Striatal Predicted Outcome and Prediction Error Activity
Gain learning is depicted on the left and loss learning on the right. The SPM images and contrast estimates show the significant striatal interaction effects (p < 0.05
FWE corrected) comparing Parkinson’s disease (PD) patients with problem gambling or shopping (DD) and PD controls on and off dopamine agonists (DA)
(repeated-measures ANOVA).
(A) Gain predicted outcome (top) and positive prediction error (bottom).
(B) Loss predicted outcome (top) and negative prediction error (bottom).
(C) Ventral striatal prediction error activity. The bar graphs show the area under the curve (AUC) of the fitted event time course ROI analysis focusing on bilateral
ventral striatal (VS) activity (repeated-measures ANOVA). The left graph shows a significant group by medication interaction effect of bilateral ventral striatum for
positive prediction error during gain learning. The right graph shows a significant medication effect of bilateral ventral striatum for negative prediction error during
loss learning. The SPM images are shown at p < 0.005 uncorrected. The error bars represent standard deviation. See also Tables S4, S5, and S6.
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with problem gambling or shopping (Gain/Loss learning rate in
mean [SD]: Gambling off DA 0.23 [0.08]/0.27 [0.04], Gambling
on DA 0.51 [0.06]/0.15 [0.04], Shopping off DA 0.20 [0.05]/0.33
[0.10], Shopping on DA 0.46 [0.10]/0.20 [0.09], p = 0.53/0.41).
Imaging
For the imaging analysis, we used a reinforcement learning
model to extract trial-by-trial d and predicted outcome, which
were then used as parametric modulators in the imaging analysis
of outcome and stimuli phases, respectively. We assessed
activity corresponding to positive and negative d separately for
gain (i.e., gain and gain omissions) and loss learning (i.e., loss
and loss omissions). We compared DD patients and PD controls
on and off DA using a mixed-measures ANOVA with DA status as
a within-subject factor and susceptibility as a between-subject
factor. Given our a priori hypothesis, we also extracted the fitted
event time course of bilateral ventral striatal ROIs and compared
the area under the curves between groups using mixed-
measures ANOVA. The central coordinates for the ventral striatal
ROIs were as follows (in mm: Gain: left x = 10 to 12, y = 9–14,z =7 to12; right x = 10–17, y = 911, z =7 to11) (Loss left:
x = 7 to 9, y = 7–10, z = 10 to 16; right x = 7–15, y = 9–10,
z = 10 to 13).
In what follows, we report the common activations for
both positive d and predicted outcome during gain learning
(Table S5). We observed a group effect of greater left orbitofron-
tal cortex activity in DD patients compared to PD controls. There
was also a susceptibility by medication interaction effect local-
ized to the striatum with DA associated with greater bilateral
ventral striatal d (F(1,21) = 5.51, p = 0.01; ROI corrected)
(Figure 2C) and greater left ventral striatal predicted outcome
(p < 0.05 FWE corrected) (Figure 2A) activity in DD patients
with the opposite pattern in PD controls. Similarly, DA were asso-
ciated with greater right posterior putamen d (p < 0.05 FWE cor-
rected) (Figure 2A) activity in DD patients with the opposite
pattern in PD controls. In the ventral striatal ROI analysis, there
were no main effects (p > 0.05).
We also identified activation for both negative d and predicted
outcome during loss learning (Table S5). Here, we observed
a group effect of greater left dorsolateral putamen and lesser
bilateral orbitofrontal cortex activity in DD patients comparedNeuron 65, 135–142, January 14, 2010 ª2010 Elsevier Inc. 137
Figure 3. Negative Prediction Error Activity during
Loss Learning in Parkinson’s Disease Controls and
Normal Volunteers
The SPM images and bar graphs show the comparison of
Parkinson’s disease controls without gambling or shopping
behaviors on dopamine agonists compared to normal volun-
teers (t test, p < 0.05 FDR corrected). The left shows the right
orbitofrontal cortex and the right shows the right anterior
insula. The SPM images are shown at p < 0.005 uncorrected.
Error bars represent standard deviation. See also Table S7.
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and medication: post hoc t tests showed that DA were associ-
ated with greater (or less of a decrease in) striatal and bilateral
anterior insular activity in PD controls with the opposite observed
in DD patients. The interaction effect of the predicted outcome
activity was localized to the left ventral striatum (Figure 2B),
and the d activity was localized to the left dorsolateral striatum
(Figure 2B). There was also a medication effect with greater left
ventral striatal negative d activity on DA compared to off DA
(p < 0.05 FWE corrected; F(1,21) = 10.05, p < 0.001; ROI cor-
rected) (Figure 2C). In the ventral striatal ROI analysis, there
were no group or interaction effects (p > 0.05).
During gain learning, the activity to negative d (i.e., gain omis-
sion or a relative loss) was consistent with that of negative
d during loss learning. Thus, there was a group effect of lower
right orbitofrontal cortex activity in DD patients compared to
PD controls. There was also a medication effect with greater
right ventral striatal activity on DA compared to off DA (Table
S2). During loss learning, activity to positive d (i.e., loss omission
or a relative gain) was consistent with that of positive d during
gain learning. There was an interaction between medication
and susceptibility: DA were associated with greater right ventral
striatal activity in DD patients with the opposite pattern seen in
PD controls (Table S2).
Normal Volunteers
We also compared behavioral (model-based learning rate) and
neural d activity with age- and gender-matched normal volun-
teers. To compare normal volunteers who were tested only
once with the repeated measures of DD and PD controls on
and off DA, we used t tests for both the behavioral and imaging
analysis. For the behavioral measures, p < 0.006 (Bonferroni
correction for multiple comparisons) was considered significant.138 Neuron 65, 135–142, January 14, 2010 ª2010 Elsevier Inc.For the imaging analyses, p < 0.05 FDR corrected
was considered significant (Genovese et al.,
2002), focusing only on the regions identified in
the previous analyses (Table S3). During gain
learning, DD patients off DA had slower learning
rates compared to normal volunteers (t = 3.43, df
= 28, p = 0.002; other t test outcomes: t < 1.62,
p > 0.05). Relative to normal volunteers, DD
patients on DA had greater right posterior putamen
positive d activity whereas PD patients on DA had
the opposite with lower bilateral posterior putamen
activity. During loss learning, PD controls off DA
had slower learning rates relative to normal volun-teers (t = 3.65, df = 28, p = 0.001; other t test outcomes t < 1.60,
p > 0.05). Relative to normal volunteers, PD controls on DA had
greater (or less of a decrease in) right lateral orbitofrontal cortex
and bilateral anterior insular activity to negative d (Figure 3).
Summary
We demonstrated several findings of note. First, the effects of DA
on gain learning were observed only in the DD patients (suscep-
tibility by medication interaction). Thus, DD patients on DA had
faster gain learning rates, greater choice probability of the gain
cue and greater ventral striatal activity to positive d. Second,
the behavioral effects of DA on loss learning were observed
only in PD controls (susceptibility by medication interaction):
PD controls on DA had slower loss learning rates, lower
percentage of the ‘‘correct’’ cue selected, and lower b. Similarly,
we observed an interaction for striatal and bilateral insula activity
to negative d and loss predicted outcome corresponding with
our behavioral findings. Different striatal regions corresponded
with negative d (left dorsolateral striatum) and with predicted
outcome (left ventral striatum). Relative to normal volunteers,
PD controls on DA were also slower at loss learning and had
greater (or less of a decrease in) anterior insular and right orbito-
frontal cortex activity. Overall, DA were also associated with
greater left ventral striatal negative d activity during loss learning
compared to off DA. Third, consistent with the gain learning
observations, the findings for positive d during loss learning (i.e.,
loss omission or a relative gain) revealed a susceptibility by
medication interaction: DD patients on DA had greater right
ventral striatal activity to positive d. Finally, DD patients overall
had greater orbitofrontal cortex activity to gains and to loss omis-
sions and lower activity to losses compared to PD controls sug-
gesting overall better orbitofrontal cortex functioning in DD
patients. Relative to normal volunteers during loss learning, PD
Neuron
Gain Bias in Compulsive Disorderscontrols on DA also had greater (i.e., less of a decrease in) right
lateral orbitofrontal cortex negative d activity.DISCUSSION
We used a reinforcement learning model to deconstruct deci-
sion-making processes dysregulated by DA in a population
susceptible to compulsive behaviors. We show a critical dissoci-
ation in the effects of gain learning. DA enhanced gain learning in
a susceptible population of DD patients but not in PD controls.
Chronic exposure to DA amplified a mismatch between expecta-
tion and outcome during gain learning in DD patients convergent
with greater ventral striatal positive d activity. Hence, DD patients
had faster gain learning and greater choice bias for gain cues,
a process possibly mediated via differences in d activity. Our
findings highlight a key decision-making process dysregulated
by DA in a population susceptible to compulsive behaviors and
provide clues to mechanisms that underlie behavioral escalation
in a disorder of behavioral addiction (Zernig et al., 2007).
The study results were limited by sample size due to the diffi-
culties in recruiting DD patients on the same DA associated with
their behaviors. Recruitment of patients whose DA were discon-
tinued may implicate a different mechanism as a tolerable acute
DA challenge may only demonstrate effect at a low dose.
Chronic low doses of DA preferentially stimulate presynaptic
D2 autoreceptors and, furthermore, may not be associated
with behavioral sensitization as compared to chronic higher
doses of DA, which stimulate postsynaptic DA receptors (Loma-
nowska et al., 2004). The duration of DA withdrawal was also
limited at a mean of 21 hr due to difficulties in tolerance of motor
symptoms. However, since the groups were matched for DA
withdrawal, observed differences emphasized that the groups
differed in sensitivity to DA. To ensure that working memory
was not a confounder in the behavioral and imaging learning
outcomes, we used the number of spatial working memory
errors as a covariate in the behavioral and imaging analyses.
Furthermore, as we were interested in pathophysiological simi-
larities of decision making between the DA-related behavioral
subgroups, we included subjects with either problem gambling
or compulsive shopping behaviors. The behaviors can also
occur concurrently, suggesting overlapping mechanisms. We
did not observe any behavioral differences between the two
subgroups (Table S4).Gain Learning
The enhancement in gain learning in DD patients may reflect
either presynaptic or postsynaptic mechanisms. Enhanced
presynaptic ventral striatal dopamine release in response to
a gambling task with both win and loss outcomes has been
demonstrated in PD patients off medications with DA-induced
pathological gambling (Steeves et al., 2009). Similarly, compul-
sive levodopa use in PD, a behavior conceptually similar to
substance abuse, is associated with greater presynaptic dopa-
mine release to a levodopa challenge, an effect hypothesized
to be due to neuronal sensitization in a susceptible population
(Evans et al., 2006). Our findings are compatible with enhanced
presynaptic ventral striatal dopamine release in responseto gain-specific outcomes, possibly reflecting a premorbid
susceptibility.
Alternatively, DD patients may have different genetic polymor-
phisms resulting in a different postsynaptic dopamine receptor
profile, which may enhance the detection of the phasic dopa-
mine response. For instance, in healthy volunteers, genetic poly-
morphisms of the DDARP-32 gene, which modulate D1 receptor
plasticity, affects learning from positive outcomes (Frank et al.,
2007a). Chronic D3 receptor stimulation from DA is associated
with enhanced postsynaptic maintenance of D1 receptors (Ber-
thet et al., 2009). Thus, differences in the function or expression
of postsynaptic D1 receptors, either as a premorbid suscepti-
bility or as an adaptation to chronic D3 receptor stimulation,
may facilitate approach networks. Further genetic polymorphism
studies are required to establish whether these observations are
presynaptic or postsynaptic in nature.
Loss Learning
We show that DA were associated with slower loss learning
along with greater (or less of a decrease in) expression of a striatal
and insular negative d activity in PD controls but not in DD
patients. This medication by susceptibility interaction effect
was localized to the left dorsolateral putamen for negative
d and to the left ventral striatum for predicted outcome. Our find-
ings in PD controls confirm the effects of DA on loss learning
outcomes observed by others (Frank et al., 2004, 2007b). Our
observation that DA were associated with greater ventral striatal
activity to negative d during both gain and loss learning support
the hypothesis that DA may impair the detection of the phasic dip
in dopamine associated with avoidance learning. However, the
behavioral effect is divergent in the two subject groups, which
may reflect the interaction with other neural regions or the role
of neurotransmitters other than dopamine.
Other neural regions implicated in our study include the ante-
rior insula, orbitofrontal cortex, and dorsolateral striatum. Our
data show that during loss learning DA were associated with
greater (or less of a decrease in) bilateral anterior insular activity
in PD controls but not in DD patients. Relative to normal volun-
teers, PD controls on DA had greater bilateral anterior insular
activity. This finding highlights the role of the anterior insula,
a key region implicated in learning from negative outcomes
from both monetary loss (Pessiglione et al., 2006) and painful
stimuli (Seymour et al., 2004). Consistent with a recent report
(van Eimeren et al., 2009), we also confirmed that PD controls
may have greater impairments in orbitofrontal cortex functioning,
a region implicated in the updating and storage of value repre-
sentation to enable flexible selection of actions (Dolan, 2007).
Critically, these findings did not extend to DD patients. In our
study, PD controls had lower activity during gain learning and
greater activity (or less of a decrease) during loss learning relative
to DD patients. Similarly, only PD controls on DA had greater or-
bitofrontal cortex activity during loss learning compared to
normal volunteers. Finally, different striatal regions, such as the
dorsolateral striatum, may also be implicated in coding for nega-
tive d. This dovetails with an observation that different ventral
striatal regions have been demonstrated to code for positive
and negative d (Seymour et al., 2005). Greater disease-related
impairment of the left dorsolateral striatum in DD patients mayNeuron 65, 135–142, January 14, 2010 ª2010 Elsevier Inc. 139
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the striatum, orbitofrontal cortex, and anterior insula may act
as a neural network in PD controls to influence the learning
from negative outcomes. We also emphasize that while we
have been focusing on the potential role of dopamine, seroto-
nergic mechanisms may also be relevant and have been impli-
cated in learning from negative outcomes, possibly providing
a wider range to code for negative d outcomes in contrast to
a mechanism based upon pauses in dopaminergic firing (Daw
et al., 2002). For instance, relative differences in individual sero-
tonergic function or dorsal raphe neurodegeneration related to
PD may result in either direct serotonergic effects or interact
with dopamine to influence loss learning. Such differences in
the impact of premorbid function and degeneration of the
ascending modulatory systems remain one potential source of
the phenotypic variation manifest in the DD and PD groups.
However, we note that the contribution of serotonergic function
and that of other ascending neuromodulatory agents to behav-
ioral aberrations in this population remain unexplored.
Conclusion
Using a reinforcement learning computational model, the effect
of DA on reinforcement learning was dissociated as a function
of outcome valence in a group susceptible to compulsive behav-
iors. DA were associated with faster gain learning in DD patients.
DA in DD patients increased striatal activity to d, resulting in
a persistent ‘‘better than expected’’ outcome. The subsequent
increase invaluation of the gain cue would appear todrive a selec-
tion bias toward the gain cues. This observation may underlie the
anecdotal clinical descriptions of the onset or the escalation of
pathological gambling behaviors following a ‘‘win.’’ In contrast,
DA were associated with slower loss learning in PD controls, an
effect that engages a neural network involved in the representa-
tion of negative d. Thus, we reveal a crucial role for dopamine
function in mediating selection biases.
EXPERIMENTAL PROCEDURES
Inclusion and Exclusion Criteria
Patients with Parkinson disease (PD) and problem gambling or compulsive
shopping (DD) and PD controls were recruited from the Parkinson Disease
clinic at the National Institute of Neurological Disorders and Stroke, National
Institutes of Health (NIH). Healthy volunteers were recruited from the NIH
healthy volunteer database at NIH. Inclusion criteria for DD patients included
(1) idiopathic PD defined by the Queen Square Brain Bank criteria; (2) either
problem gambling defined by the Research Definition Criteria of the Diagnostic
and Statistical Manual of Mental Disorders, Version IV (DSM IV) (three positive
criteria) (1994), or compulsive shopping defined by McElroy’s criteria (McElroy
et al., 1994); (3) behavior onset after the initiation of DA; and (4) on the same DA
that resulted in their behavioral symptoms. Inclusion criteria for PD controls
included idiopathic PD and no history of problem gambling, shopping, hyper-
sexuality, punding, or compulsive medication use (definitions reviewed in Voon
and Fox, [2007]; and matched for gender, age (±10 years), DA type, DA dose
(±1 mg pramipexole and ±4 mg ropinorole) and presence or absence of levo-
dopa. Exclusion criteria for both groups included the presence of dementia
(DSM IV criteria), major depression or mania (DSM IV criteria) (1994), and
contraindications for MRI, including deep-brain stimulation. Healthy controls
were age (±5 years) and gender matched. Subjects were assessed using the
clinician-rated semistructured interview, the Structured Clinical Interview for
the Diagnosis of DSM IV psychiatric disorders, for the presence of affective,
anxiety, and substance use disorders and also for the presence of visual hallu-140 Neuron 65, 135–142, January 14, 2010 ª2010 Elsevier Inc.cinations or illusions. The study was approved by the NIH Research Ethics
Board and all subjects consented to the study.
Task Description
All subjects performed the probabilistic learning task. DD patients and PD
controls performed the working memory and set shifting tasks.
Probabilistic Learning Task
In the learning task, subjects chose between stimuli pairs with fixed probabi-
listic contingencies divided into three conditions: gain, loss, and neutral (30
trials/condition/run; 3 runs). For example, in the gain condition, one stimulus
pair was associated with an 80:20 probability of winning $10:$0 and the
opposing stimulus pair with an 80:20 probability of winning $0:$10. Similarly,
in the loss and neutral conditions, one stimulus pair was associated with an
80:20 probability of losing $10:$0 or ‘‘looking’’ at $10:$0, respectively, with
the opposite contingencies in the other stimulus pair. Subjects viewed the
cues (4.5 s), selected their choice (1 s), and viewed the outcomes (3 s), fol-
lowed by a fixation point (0.5 s) for a total of 90 trials lasting 13.5 min per
run. The three conditions were randomly presented during each run. The
stimuli positions were randomly presented on the left or right side of the
screen. Subjects pressed either the left or right button of the Lumina response
box with their right hand to indicate whether they chose the left or right choice.
Subjects were instructed to maximize their earnings and were told they would
receive a proportion of their earnings. The earnings ranged from $10 to $30.
The task was coded using e-PRIME.
Subjects underwent 30 min (two sessions) of practice prior to the functional
MRI (fMRI) study with one of the sessions occurring immediately before scan-
ning using stimuli pairs that differed from the scanning stimuli. Subjects who
were unable to undergo fMRI testing similarly underwent 30 min of practice.
The reported data represent behavioral outcomes of the scanning study and
do not include the training data. Subjects were tested in a pseudorandomized
order at least 3 days apart either 2 hr after DA administration or a mean of 21.3
hr (SD 4.4 hr) after withholding DA. Levodopa dose was held overnight where
possible.
MRI Scanning and Preprocessing
MRI scanning was performed on a 1.5T General Electric scanner with an 8
channel head coil. Thirty-eight continuous axial slices (slice thickness 3 mm,
gap 1 mm) were acquired using T2*-weighted echo planar images at
a temporal resolution of 2.66 s, echo time 33 ms, flip angle 90, matrix 64 3
64 with interleaved acquisition. To minimize head movement, all subjects
were stabilized with an elastic bandage wrapped around the forehead and
tightly packed foam padding surrounding the head. Images were projected
onto a screen at the foot of the subject. Subjects viewed the stimuli via a mirror
placed above the top of the head coil reflecting images from the screen. The
first four echo planar image volumes were discarded from analysis as dummy
scans to allow for magnetization to reach steady state. The imaging data was
preprocessed using SPM5 (www.fil.ion.ucl.ac.uk/spm). The data were
adjusted for slice timing, realigned to the first image of the first run, normalized
to the Montreal Neurological Institute atlas, and smoothed using an 8 mm
Gaussian kernel. Head motion parameters were used as regressors of no
interest in the first level analysis.
Data and Statistical Analysis
Model-Based Outcome Measures
The Q-learning algorithm was used to calculate the model-based parameters
of learning rate (a), temperature (b), and predicted outcome of the cues (qA).
These measures were obtained separately for the gain and loss learning condi-
tions. The algorithm computed the predicted outcome of each stimulus-pair
choice (qA or qB). For example, for choice A, the predicted outcome of cue
A at t + 1 was calculated as follows:qAðt+ 1Þ =qAðtÞ +adðtÞ
dðtÞ =prediction error= actual outcomeðtÞ  qAðtÞ:
Neuron
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at +10 for gain and 10 for loss. The probability of choosing each option (pA)
was calculated using a standard softmax function, a stochastic decision rule






The algorithm iteratively samples a and b parameters from 0.01 to 1 to deter-
mine the optimal pair that best estimated the actual choices of each individual.
The optimal pair of a and b parameters was determined using the maximum log
likelihood. The log likelihood was determined for each combination of a and
b parameters (between 0 and 1), and the pair corresponding to the maximum
log likelihood for each individual was used as the optimal parameter for that
individual. The optimal fit a and b for each individual’s behavioral choices
were compared between groups. To ensure the model-based predicted
outcome was not due to differences in individual a and b, the mean model-
based predicted outcome for each individual was obtained using a single
set of optimal a and b parameters across groups. The algorithm was pro-
cessed using MATLAB version 7.5.
Behavior-Based Outcome Measures
The percentage of actual ‘‘correct’’ choices was calculated as ‘‘correct’’
choice/total choices, where ‘‘correct’’ choices were defined as selection of
the high probability gain cue and the low probability loss cue. The amount of
money won and lost during the gain and loss conditions were calculated.
Statistical Analysis
Patient characteristics were compared using Fisher’s exact test for categorical
variables or unpaired t test or ANOVA for continuous variables. The behavioral
outcomes were analyzed using a mixed-measures ANOVA with medication
status as a within subject comparison and patient group as a between subject
comparison. Spatial working memory errors were used as a covariate. To
parallel the imaging analysis, the behavioral analysis assessing normal volun-
teers was conducted using separate t tests comparing normal volunteers with
DD patients or PD controls on or off DA. p = 0.006 Bonferroni corrected for
multiple comparisons was considered significant. To assess if gain and loss
learning were related, we conducted regression analyses between a, b, and
actual choices for gain and loss learning. All statistics were conducted using
SPSS version 16.0.Imaging Analysis
We conducted separate imaging analyses for positive and negative d and pre-
dicted outcomes for both gain and loss conditions (total of six analyses). The
trial-by-trial d and predicted outcome were extracted using the reinforcement
learning model with individual optimal a and b parameters. dwas used as para-
metric modulator for the 3 s outcome phase and predicted outcome was used
as a parametric modulator for the 3 s stimulus phase. The choice phase was
also modeled. To compare d and predicted outcome activity between DD
patients and PD controls in the group analysis, we used a mixed-measures
ANOVA with DA status as a within-subject factor and susceptibility as
a between-subjects factor with spatial working memory as a covariate. We
focused on the striatum, amygdala, orbitofrontal cortex, and insular cortices,
regions previously implicated in d activity with significance defined as p <
0.05 whole-brain FDR corrected. As we had a specific a priori hypothesis
focusing on ventral striatal d activity, we also used a ROI analysis. The coordi-
nates of the ROIs were determined separately for gain and loss learning based
on the peak local maximum ventral striatal activity for each group (DD patients
and PD controls on and off DA) (Duvernoy, 1999). In cases in which only
a unilateral peak could be identified, the mirror coordinates in the opposite
hemisphere were used to identify the opposite ROI. Thus, eight different
sets of bilateral ventral striatal ROIs were constructed with a 0.5 mm radius.
We then extracted fitted event time course analyses using MarsBar (MARSeille
Boite A Region d’Interet) of these ventral striatal ROIs and compared the area
under the curve (Pessiglione et al., 2006). We compared the area under the
curve between DD patients and PD controls on and off DA using a mixed-
measures ANOVA with DA status as a within-subject factor and susceptibility
as a between-subject factor. To assess differences from normal volunteers,
we used separate t tests to assess normal volunteers versus DD patients or
PD controls on or off DA using t tests (since the data included bothrepeated-measures and single measures) with SWM as a covariate. As we
were interested in whether the previously identified imaging data differed
from normal volunteers, we focused on the previously identified regions with
FDR p < 0.05 corrected considered as significant. We compared positive
d for gain learning and negative d for loss learning.
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